Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-02
2010-10-19
Fay, Zohreh A (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S530000, C514S573000
Reexamination Certificate
active
07816399
ABSTRACT:
It is intended to provide medicines having a higher ocular tension-lowering effect on ocular hypertension and glaucoma. Because of showing an excellent effect of lowering ocular tension, medicines comprising a combination of a prostaglandin compound with an NO-donating compound are useful in treating ocular hypertension and glaucoma.
REFERENCES:
patent: 11-171764 (1999-06-01), None
patent: 11-500122 (1999-06-01), None
patent: 11-189537 (1999-07-01), None
patent: 2001-81048 (2001-03-01), None
patent: 00/38689 (2000-07-01), None
Medline Abstarct 07174609, 1996. Masuda.
Okumura T. et al., Canine retinal arterial and arteriolar dilation Induced by nipradilol, a possible glaucoma therapeutic, Pharmacology, 1996, vol. 53, No. 5, pp. 302 to 310.
Albach C. et al, Uber Die Drucksenkende Wirkung Von Latanoprost 0, 005 % Klinische Monatsblatter fur Augenheilkunde, 1998, vol. 212. No. 5, pp. 268 to 269.
Drago Filippo et al., Latanoprost exerts neuroprotective activity in vitro and viro, Experimental Eye Research. Apr. 2001 vol. 72, No. 4, pp. 479 to 486 & Databae CAPLUS on STN, American Chemical Society (ACS), (Columbus, OH, USA). DN 135:71229.
Okumura T., et al., “Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic”, Pharmacology, vol. 53, No. 5, pp. 302-310 1996.
Albach C., et al., Über Die Drucksenkende Wirkung Von Latanoprost 0,005%, Klinische Monatsblatter Fur Augenheilkunde, vol. 212, No. 5, pp. 268-269 1998.
Drago Filippo, et al., “Latanoprost exerts neuroprotective activity in vitro and in vivo”, Experimental Eye Research, vol. 72, No. 4, pp. 479-486 2001.
Elke Lütjen-Drecoll, et al., “Morphological Study of the Anterior Segment of Cynomolgus Monkey Eyes Following Treatment with Prostaglandin F2”, Exp. Eye Res. vol. 47, pp. 761-769 1988.
Cameron Millar, et al., Investigative Ophthalmology & Visual Science, vol. 36, No. 12, pp. 2461-2465 1995.
Sardar Y.K. Yousufzai, et al., Exp. Eye Res. vol. 63, pp. 305-310, 1996.
Scott A. Waldman, et al., The Journal of Biological Chemistry, vol. 259, No. 23, pp. 14332-14334 1984.
James A. Nathanson, et al., European Journal of Pharmacology, vol. 147, pp. 155-156 1988.
Daniela Salvemini, et al., Proc. Natl. Acad. Sci. USA, vol. 90, pp. 7240-7244 1993.
Furchtgott, Robert F., et al., “The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine”,Nature, vol. 288, Nov. 27, 1980, pp. 373-376.
Ignarro, Louis J., et al., “Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide”,Proceedings of the National Academy of Sciences USA, vol. 84, Dec. 1987, pp. 9265-9269 (Medical Sciences).
Murad, Ferid, et al., “Properties and Regulation of Guanylate Cyclase and Some Proposed Functions for Cyclic GMP”,Advances in Cyclic Nucleotide Research, vol. 11 (edited by P. Greengard and G.A. Robison), Raven Press, New York, 1979, pp. 175-204.
Koike Junpei
Masuda Kanako
Orihashi Masahiro
Fay Zohreh A
Kowa Company Ltd.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Teika Pharmaceutical Co., Ltd.
LandOfFree
Medicines and medicinal kits does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicines and medicinal kits, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicines and medicinal kits will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159910